drugset / Trial / NCT04856774
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2024-03-30
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 30 mg/kg | Intravenous |